Sarepta Stock Decline

Order byBest matchMost fresh

Sarepta stock extends decline

Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

· 2d · on MSN

Sarepta stock extends decline as company declines FDA call to withdraw drug

· 1d

Sarepta Shares Slide Again as Drugmaker Bows to FDA Pressure to Pause Gene Therapy

· 3h

InnovationRx: Sarepta Blinks In Showdown With FDA

Last week, in a remarkable showdown, Sarepta Therapeutics refused to stop distribution of Elevidys, its therapy for the muscle-wasting disease Duchenne muscular dystrophy as the FDA had requested.

· 1d

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

STAT · 1d

Sarepta Therapeutics’ Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says

Hoodline3d

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

GEN - Genetic Engineering and Biotechnology News3d

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after announcing of a restructuring that entailed cutting about 500 jobs,

23h

Opendoor Technologies shares bounce again after turbulent trading

Opendoor Technologies shares are up nearly 12% as traders continue to buy the meme stock after [Monday's extreme volatility](

Stock market today: S&P 500 crosses 6,300, Nasdaq notches record with Big Tech set to take earnings spotlight

US stocks closed mixed on Monday, but the Nasdaq Composite and S&P 500 managed to notch fresh records. Wall Street began a busy week of Big Tech-highlighted earnings and eyed the

Forbes3y

What’s Next For Sarepta Stock After A 12% Fall?

Sarepta Therapeutics stock declined 14% over the last five trading days (one week), compared to broader market (S&P500) decline of 0.03%; A change of -14% or more over five trading days (one week ...